



**Date: 15 August 2019**  
**Sydney, Australia**

ASX Limited  
20 Bridge Street  
SYDNEY NSW 2000

## **Lead Manager Appointed for Proposed Nyrada IPO**

### **KEY HIGHLIGHTS**

---

- **Noxopharm subsidiary, Nyrada Inc, to raise A\$8 million through issue of CDIs**
  - **Proposed ASX listing**
  - **Alto Capital appointed as Lead Manager**
  - **Funds to accelerate development of three first-in-class drug assets**
- 

**SYDNEY, 15 August 2019:** Noxopharm Ltd (**'Noxopharm'**) (ASX:NOX) is pleased to announce the appointment of Alto Capital as the Lead Manager for the proposed capital raising and ASX listing of its subsidiary company, Nyrada Inc (**'Nyrada'** or **'The Company'**).

Nyrada is a U.S. biotechnology company that intends seeking a listing as a foreign entity on the ASX through the issuance of CHESS Depositary Interests (CDIs).

The funds to be raised in the proposed IPO are intended to further the development of its three drug programs, each of which are first-in-class and in areas of significant unmet need and considerable international pharma industry activity. All three programs are the result of innovative Australian research.

The lead program covers the development of a drug to lower blood cholesterol. It is intended as an oral PCSK9-inhibiting drug to be a companion drug to statins in the significant proportion of patients whose blood cholesterol levels don't reach target levels with statins alone, or in those patients unable to tolerate adequate dosages of statins. This is a market estimated to be in excess of 50 million people in the U.S. alone and held to be worth US\$15 billion-plus annually. Nyrada believes it has a major competitive advantage in the growing field of PCSK9 inhibition and will employ the funds to bring its lead candidate into the clinic.

The second lead program involves a neuroprotectant drug intended to protect the brain from a form of secondary damage known as excitotoxicity. Excitotoxicity is believed to account for much of the long-term disability associated with stroke or traumatic brain injury (TBI) such as severe concussion from contact sports or as a result of a vehicle accident or military misadventure. This is a very large area of unmet need that constitutes a significant community cost in terms of rehabilitation and long-term care. Nyrada is confident that, in collaboration with the Translational Neurosciences Unit of The University of NSW, Sydney, it has developed a first-in-class drug candidate designed to be given to stroke and TBI



patients in the days following the injury an intended to limit the extent of brain damage and reduce the incidence and severity of long-term disability.

The third lead program involves peripheral nerve crush injury, a common form of which is sciatica. Nyrada is in the early stages of a program to develop an anti-inflammatory drug capable of providing pain relief in a non-addictive and well-tolerated way. A key development here has been the development of a proprietary technology platform designed to overcome the restrictive blood-nerve barrier, so allowing drugs to attain high drug levels within nerve tissue.

The Prospectus for the proposed IPO is well advanced and which the Company hopes to be able to provide to the market in the coming weeks pursuant to regulatory approval.

Noxopharm intends to provide a priority offer in the proposed Nyrada IPO to existing Noxopharm shareholders. The details of this currently are being finalised and further information will be available in due course.

Alto Capital (AFSL: 279099) specialises in raising capital for companies via Initial Public Offerings, Rights Issues and Placements. Alto Capital currently is active and well-versed in the biotech space. Alto Capital is a full-service advisory firm offering investment advice to both retail and sophisticated clients.

Investors interested in pre-registering for the IPO should contact Alto Capital via the contact details below.

#### **About Noxopharm**

Noxopharm is a clinical-stage Australian drug development company with offices in Sydney and New York. The Company has a primary focus on the development of Veyonda<sup>®</sup> and is the major shareholder in Nyrada Inc.

[www.noxopharm.com](http://www.noxopharm.com)

#### **Investor & Corporate Enquiries:**

Prue Kelly

M: +61 459 022 445

E: [info@noxopharm.com](mailto:info@noxopharm.com)

#### **Alto Capital Enquiries:**

Caue Rodrigues

T: +61 8 9223 9819

E: [caue@altocapital.com.au](mailto:caue@altocapital.com.au)

#### **Forward Looking Statements**

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company’s control that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement. No representation, warranty or assurance (express or implied) is given or made by Noxopharm that the forward-looking statements contained in this announcement are accurate and undue reliance should not be placed upon such statements.